B-cell lymphoma 2 inhibitor - Ontology Report

AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]

PMID:32802178

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

Bag3

BAG cochaperone 3

decreases response to substance
multiple interactions

BAG3 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]

PMID:23341456

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

Bax

BCL2 associated X, apoptosis regulator

affects folding
multiple interactions

ABT-737 affects the folding of BAX protein
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [ABT-737 co-treated with hydroquinone] results in increased expression of BAX protein; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]

PMID:17097560 PMID:17200714 PMID:21880625 PMID:28843007

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

Bcl2

BCL2, apoptosis regulator

multiple interactions
decreases response to substance

ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Vorinostat]
BCL2 protein modified form results in decreased susceptibility to ABT-737
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased phosphorylation of BCL2 protein] which results in increased susceptibility to ABT-737; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [ABT-737 results in decreased activity of BCL2 protein] which results in increased susceptibility to fosbretabulin; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]

PMID:17097560 PMID:17200714 PMID:19060243 PMID:20104024 PMID:24321340 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

Bcl2l1

Bcl2-like 1

multiple interactions
increases expression

ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Vorinostat]
ABT-737 results in increased expression of BCL2L1 protein alternative form
ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]

PMID:18628207 PMID:19060243 PMID:21256112

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

Bcl2l11

Bcl2-like 11

multiple interactions
increases response to substance

[ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]
BCL2L11 protein results in increased susceptibility to ABT-737

PMID:17097560 PMID:17200714 PMID:20038611 PMID:23341456

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

Becn1

beclin 1

multiple interactions

ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]]

PMID:18628207 PMID:32061152

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

Bid

BH3 interacting domain death agonist

multiple interactions

[ABT-737 co-treated with Celecoxib] results in increased cleavage of BID protein

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

Braf

B-Raf proto-oncogene, serine/threonine kinase

multiple interactions

ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]

PMID:27689874

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

Casp3

caspase 3

increases cleavage
increases activity
multiple interactions

ABT-737 results in increased cleavage of CASP3 protein
ABT-737 results in increased activity of CASP3 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP3 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP3 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]

PMID:19010845 PMID:19773376 PMID:20038611 PMID:20104024 PMID:23353698 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

Casp7

caspase 7

increases activity

ABT-737 results in increased activity of CASP7 protein

PMID:20038611

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

Casp8

caspase 8

increases cleavage
multiple interactions

ABT-737 results in increased cleavage of CASP8 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP8 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

Casp9

caspase 9

increases activity
multiple interactions
increases cleavage

ABT-737 results in increased activity of CASP9 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP9 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP9 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]

PMID:20104024 PMID:23353698 PMID:30461186 PMID:33662508

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

H2ax

H2A.X variant histone

multiple interactions

[ABT-737 co-treated with hydroquinone] results in increased expression of H2AX protein

PMID:28843007

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

Hgf

hepatocyte growth factor

multiple interactions

ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]

PMID:27689874

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

Krt18

keratin 18

increases cleavage

ABT-737 results in increased cleavage of KRT18 protein

PMID:19010845

NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166

Map1lc3b

microtubule-associated protein 1 light chain 3 beta

multiple interactions

MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

Mcl1

MCL1 apoptosis regulator, BCL2 family member

decreases response to substance
multiple interactions

MCL1 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; [Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]

PMID:17097560 PMID:17688235 PMID:21880625 PMID:23341456 PMID:32802178

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

Met

MET proto-oncogene, receptor tyrosine kinase

multiple interactions

ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]

PMID:27689874

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

Mki67

marker of proliferation Ki-67

multiple interactions
decreases expression

[ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
ABT-737 results in decreased expression of MKI67 protein

PMID:19773376

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

Nanog

Nanog homeobox

decreases expression

ABT-737 results in decreased expression of NANOG protein

PMID:23918355

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116

Parp1

poly (ADP-ribose) polymerase 1

multiple interactions

[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein; [ABT-737 co-treated with hydroquinone] results in increased cleavage of PARP1 protein; ABT-737 inhibits the reaction [hydroquinone affects the localization of PARP1 protein]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]

PMID:28843007 PMID:32802178

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

Pik3c3

phosphatidylinositol 3-kinase, catalytic subunit type 3

multiple interactions

PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]

NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048

Pmaip1

phorbol-12-myristate-13-acetate-induced protein 1

increases response to substance

PMAIP1 protein results in increased susceptibility to ABT-737

PMID:17688235

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

Rassf1

Ras association domain family member 1

multiple interactions

ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Cisplatin]; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide]

PMID:21880625

NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164

Sqstm1

sequestosome 1

multiple interactions

[Celecoxib co-treated with ABT-737] results in decreased expression of SQSTM1 protein; ABT-737 promotes the reaction [Silicon Dioxide results in decreased expression of SQSTM1 protein]

PMID:20104024 PMID:32061152

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

Tp53

tumor protein p53

multiple interactions

[ABT-737 co-treated with hydroquinone] results in increased expression of TRP53 protein

PMID:28843007

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

Usp7

ubiquitin specific peptidase 7

multiple interactions

USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]

PMID:32802178

NCBI chr10:6,880,684...6,925,355
Ensembl chr10:6,828,795...6,925,355

navitoclax

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Bak1

BCL2-antagonist/killer 1

multiple interactions

[navitoclax co-treated with Vorinostat] affects the activity of BAK1 protein

PMID:21652541

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

Bax

BCL2 associated X, apoptosis regulator

multiple interactions

[navitoclax co-treated with Vorinostat] affects the activity of BAX protein

PMID:21652541

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

Birc5

baculoviral IAP repeat-containing 5

decreases expression
multiple interactions

navitoclax results in decreased expression of BIRC5 protein
[MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]

PMID:28947240

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

Casp3

caspase 3

increases cleavage
multiple interactions

navitoclax results in increased cleavage of CASP3 protein
[navitoclax co-treated with GSK923295] results in increased activity of CASP3 protein; [navitoclax co-treated with Vorinostat] results in increased activity of CASP3 protein

PMID:21562047 PMID:21652541 PMID:38258067

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

Casp9

caspase 9

increases cleavage

navitoclax results in increased cleavage of CASP9 protein

PMID:21562047 PMID:28947240

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

Gsn

gelsolin

increases cleavage

navitoclax results in increased cleavage of GSN protein

PMID:21562047

NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402

Mtor

mechanistic target of rapamycin kinase

affects response to substance
multiple interactions

MTOR protein affects the susceptibility to navitoclax
[MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein

PMID:28947240

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

Parp1

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

[MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein; rucaparib promotes the reaction [navitoclax results in increased cleavage of PARP1 protein]

PMID:28947240 PMID:32927276

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

venetoclax

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Abcb1a

ATP binding cassette subfamily B member 1A

multiple interactions

[venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]] which results in decreased export of Daunorubicin; venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]

PMID:34963561

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

Abcg2

ATP binding cassette subfamily G member 2

affects binding

venetoclax binds to ABCG2 protein

PMID:33954893

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

Bak1

BCL2-antagonist/killer 1

affects folding

venetoclax affects the folding of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

Bax

BCL2 associated X, apoptosis regulator

affects folding

venetoclax affects the folding of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

Bbc3

Bcl-2 binding component 3

affects response to substance
multiple interactions

BBC3 protein affects the susceptibility to venetoclax
2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [BBC3 protein affects the susceptibility to venetoclax]; BBC3 protein affects the susceptibility to [venetoclax co-treated with pitavastatin]

PMID:37956312

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

Bcl2

BCL2, apoptosis regulator

decreases activity
decreases expression
multiple interactions

venetoclax results in decreased activity of BCL2 protein
venetoclax results in decreased expression of BCL2 protein
[9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of BCL2 protein; [mivebresib co-treated with venetoclax] results in decreased expression of BCL2 protein

PMID:26214592 PMID:30647404 PMID:37754227

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

Bcl2l1

Bcl2-like 1

decreases expression
multiple interactions

venetoclax results in decreased expression of BCL2L1 protein
[mivebresib co-treated with venetoclax] results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

Birc5

baculoviral IAP repeat-containing 5

multiple interactions

[sepantronium co-treated with venetoclax] results in decreased expression of BIRC5 protein

PMID:31837377

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

Btrc

beta-transducin repeat containing E3 ubiquitin protein ligase

multiple interactions

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]

NCBI chr 1:244,210,299...244,380,126
Ensembl chr 1:244,210,314...244,376,721

Casp3

caspase 3

multiple interactions
increases cleavage

[venetoclax co-treated with sepantronium] results in increased cleavage of CASP3 protein; venetoclax inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of CASP3 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of CASP3 protein]

PMID:31837377 PMID:34303041 PMID:34861246

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

Casp9

caspase 9

multiple interactions

[venetoclax co-treated with sepantronium] results in increased cleavage of CASP9 protein

PMID:31837377

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

Ccl2

C-C motif chemokine ligand 2

multiple interactions

Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCP1 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

Cdk6

cyclin-dependent kinase 6

multiple interactions

[mivebresib co-treated with venetoclax] results in decreased expression of CDK6 protein

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

Flt3

Fms related receptor tyrosine kinase 3

decreases expression
multiple interactions

venetoclax results in decreased expression of FLT3 protein
9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- promotes the reaction [venetoclax results in decreased expression of FLT3 protein]; [9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of FLT3 protein

PMID:37754227

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

Mapk1

mitogen activated protein kinase 1

multiple interactions

[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK1 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

Mapk3

mitogen activated protein kinase 3

multiple interactions

[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK3 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

Mcl1

MCL1 apoptosis regulator, BCL2 family member

increases expression
decreases expression
multiple interactions

venetoclax results in increased expression of MCL1 protein
venetoclax results in decreased expression of MCL1 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; [mivebresib co-treated with venetoclax] results in decreased expression of MCL1 protein; [sepantronium co-treated with venetoclax] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]

PMID:30647404 PMID:31837377 PMID:35561756 PMID:37754227

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

Myc

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[mivebresib co-treated with venetoclax] results in decreased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

Nox4

NADPH oxidase 4

multiple interactions

[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 protein; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 protein

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

Parp1

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

[mivebresib co-treated with venetoclax] results in increased cleavage of PARP1 protein; [venetoclax co-treated with sepantronium] results in increased cleavage of PARP1 protein; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of PARP1 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of PARP1 protein]

PMID:30647404 PMID:31837377 PMID:34861246

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

Pmaip1

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions
affects response to substance
increases expression

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]
PMAIP1 protein affects the susceptibility to venetoclax
venetoclax results in increased expression of PMAIP1 protein

PMID:30647404 PMID:35561756 PMID:37956312

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

Sp1

Sp1 transcription factor

multiple interactions

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of and results in increased stability of SP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

Sqstm1

sequestosome 1

multiple interactions

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein; [venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]